102721-76-6

Upstream product

• 75-52-5 nitromethane 
• 18805-25-9 methyl carbonimidodithioic acid dimethyl ester 
• 74-89-5 methylamine 
• 13623-94-4 1,1-di(methylsulfanyl)-2-nitroethylene 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 

Downstream Products

• 54252-45-8 N,N'-dimethyl-2-nitro-1,1-ethenediamine 
• 74-93-1 methylthiol 
• 66357-35-5 ranitidine 
• 76963-41-2 nizatidine 
• 1233536-62-3 C₁₄H₁₇N₃O₂ 
• 1233536-63-4 C₁₃H₁₅N₃O₂ 
• 120738-89-8 nitenpyram 
• 1438418-05-3 4-(2-chlorophenyl)-6-methyl-2-(methylamino)-3-nitro-4H-pyrano[3,2-c]quinolin-5(6H)-one 
• 1438418-06-4 4-(3-fluorophenyl)-6-methyl-2-(methylamino)-3-nitro-4H-pyrano[3,2-c]quinolin-5(6H)-one 
• 1438418-07-5 4-(3-bromophenyl)-6-methyl-2-(methylamino)-3-nitro-4H-pyrano[3,2-c]quinolin-5(6H)-one 
• 1438418-08-6 6-methyl-2-(methylamino)-3-nitro-4-(4-nitrophenyl)-4H-pyrano[3,2-c]quinolin-5(6H)-one 
• 1438418-10-0 4-(2,3-dichlorophenyl)-6-methyl-2-(methylamino)-3-nitro-4H-pyrano[3,2-c]quinolin-5(6H)-one 
• 1438418-11-1 4-(2,4-dichlorophenyl)-6-methyl-2-(methylamino)-3-nitro-4H-pyrano[3,2-c]quinolin-5(6H)-one 
• 1438418-12-2 4-(2,5-dimethoxyphenyl)-6-methyl-2-(methylamino)-3-nitro-4H-pyrano[3,2-c]quinolin-5(6H)-one 

Relevant academic research and scientific papers

Synthesis of Spiro[indoline-3,4′-pyrano[3,2-c]chromene]diones

A new series of isatin-based spiro-fused derivatives were prepared, via three-component reaction of N-alkyl-1-(methylthio)-2-nitroethenamine derived from the addition of various amines to nitroketene dithioacetal with isatin derivatives and 4-hydroxycouma

Design, synthesis, and particular biological behaviors of chain-opening nitromethylene neonicotinoids with cis configuration

On the basis of the structure of heterocyclic-fused cis configuration derivatives and chain-opening neonicotinoids, two series of novel chain-opening tetrahydropyridine analogues were designed and synthesized. The preliminary bioassay tests were determined on cowpea aphid (Aphis craccivora) and armyworm (Pseudaletia separata Walker). The results showed that some of the target compounds exhibited repellent effects, whereas others showed good insecticidal activities.

Rapid and catalyst free synthesis of new bis(benzo[: G] chromene) and bis(pyrano[3,2- c] chromene) derivatives and optimization of reaction conditions using response surface methodology

4,4′-(1,4-phenylene)bis(2-(alkylamino)-3-nitro-4H-benzo[g]chromene-5,10-dione) and 4,4′-(1,4-phenylene)bis(2-(alkylamino)-3-nitropyrano[3,2-c]chromen-5(4H)-one) derivatives are synthesized by a one-pot, multi-component reaction of N-alkyl-1-(methylthio)-2

Synthesis and analgesic activity evaluation of some agmatine derivatives

A series of N,N′-disubstituted-2-nitroethene-1,1-diamine and N,N′-disubstituted-N″-cyanoguanidine derivatives were prepared and evaluated for in vivo analgesic activity. The blood brain barrier (BBB) VolSurf model was used to predict the BBB permeation profiles of our synthesized compounds. Some compounds show both remarkable analgesic activity and good BBB permeation profiles, and these compounds might be developed for treatment of opioid tolerance and dependence.

A simple and environmentally benign synthesis of novel spiro[indoline-3,5′-pyrano[2,3-d]pyrimidine] derivatives in water

Abstract: A green, convenient, and efficient one-pot synthesis of a new class of spiro[indolinepyranopyrimidine] derivatives was achieved in good yields by the multi-component reaction of N-alkyl-1-(methylthio)-2-nitroethenamine derived from the addition

POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

A 1 - methylamino -1 - methylthio -2 - nitroethylene method for the preparation of

The invention relates to the field of chemical synthesis, and especially relates to a preparation method for 1-methylamino-1-methylthio-2-nitroethylene. The preparation method comprises: in the presence of a solvent, taking nitromethane, carbon disulfide and potassium hydroxide to perform a condensation reaction, so as to obtain a compound of a formula II; taking the compound of the formula II and methylamine to perform amination reaction, so as to obtain a compound of a formula III and hydrosulfide ion which is reacted with an acid for generating hydrogen sulfide; taking the compound of the formula III, a methylation reagent and an alkali to perform a methylation reaction, so as to obtain 1-methylamino-1-methylthio-2-nitroethylene crude product; and refining the crude product, so as to obtain 1-methylamino-1-methylthio-2-nitroethylene. The provided preparation method for 1-methylamino-1-methylthio-2-nitroethylene eliminates generation of a main gas pollution source methyl mercaptan, guarantees product quality, substantially reduces usage amount of the raw materials, shortens the reaction time and improves the product yield.

An efficient synthesis of N-substituted 3-nitrothiophen-2-amines

A novel protocol for the synthesis of 3-nitro-N-aryl/alkylthiophen-2-amines in good yields from the reaction of α-nitroketene N,S-aryl/alkylaminoacetals and 1,4-dithiane-2,5-diol in the presence of K2CO3 in refluxing ethanol is descr

Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement

The inhibition of human glutaminyl cyclase (hQC) has come into focus as a new potential approach for the treatment of Alzheimer's disease. The hallmark of this principle is the prevention of the formation of Aβ 3,11(pE)-40,42, as these Aβ-speci

Nitroketene-s,n-acetals as precursors for nitroacetamides and the elusive nitrothioacetahides

1-Amino-1-methylthio-2-nitroethenes (2) can be converted in high yields to the Nitroacetamides (3) by Hg2+ catalysed hydrolysis and to the Nitrothioacetamides (4) by Na2S in ethanol-acetic acid.